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Summary If genetic testing for breast and ovarian cancer predisposition is to become available within a public health care system there
needs to be a rational and cost-effective approach to mutation analysis. We have screened for BRCA1 mutations in 230 women with breast
cancer, all from the Wessex region of southern England, in order to establish the parameters on which to base a cost-effective regional
mutation analysis strategy. Truncating mutations were detected in 10/155 (6.5%) consecutive cases selected only for diagnosis under the age
of 40 (nine of these ten women had a strong family history of breast or ovarian cancer), 3/61 (4.9%) bilateral-breast cancer cases (all three
mutations occurring among women for whom the first cancer was diagnosed under 40 years) and 8/30 (26.6%) breast cancer cases
presenting to the genetics clinic (for whom a strong family history of breast and/or ovarian cancer was present). Ten different mutations were
detected in 17 families, but three of these accounted for 10/17 (59%) of the families. The cost of screening the population for mutations in the
entire BRCA1 gene is unacceptably high. However, the cost of screening a carefully selected patient cohort is low, the risk of misinterpretation
much less and the potential clinical benefits clearer.
Keywords: BRCA1; breast cancer; ovarian cancer; mutation analysis
With the cloning ofBRCAI in 1994 (Miki et al, 1994) and BRCA2
in 1995 (Wooster et al, 1995) it is now possible to screen breast or
ovarian cancer patients for the presence of germline mutations.
Together these genes account for about 75% of families with a
highly penetrant dominantly inherited breast and/or ovarian cancer
family history. There is at least one other highly penetrant breast
cancer predisposition gene to be discovered (Rebbeck et al, 1997;
Schubert et al, 1997; Serova et al, 1997) and undoubtedly many
others of lower penetrance. Mutations in BRCAJ and BRCA2 are
scattered throughout these very large genes and current methods of
mutation analysis are far from perfect. Most of the available tech-
niques detect only about 70-80% of causative mutations. A nega-
tive result from a mutation screen, in most circumstances, means
very little in terms of altering the breast cancer risk to other
relatives (Eeles, 1996; Healy, 1997). In families with a striking
occurrence of apparently dominantly inherited breast cancer,
however, the finding ofa mutation can greatly refine the prediction
of cancer risk and help to inform clinician and patient alike when
making decisions about, for example, preventive surgery or cancer
treatment.
Mutation analysis is already available in a few genetics centres
in the UK as part of a comprehensive molecular genetics service.
As referrals for advice about inherited cancer risks escalate so do
expectations for genetic testing to be provided. A rational
approach to such testing is needed. We have reviewed three clini-
cally selected groups for whom testing might be indicated and
performed a comprehensive screen for mutations in BRCA1. Using
these data from our local population the sensitivity and cost of
testing in a variety of situations has been assessed.
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MATERIALS AND METHODS
A total of 230 women diagnosed with breast cancer were grouped
according to the following criteria.
Group 1
A total of 155 women diagnosed with breast cancer before 40 years
of age were systematically ascertained through breast clinics in
Wessex. They were invited to take part in a research study, the
primary goal of which was to ascertain and verify family histories
for segregation analysis. These were consecutively ascertained
without regard to family history (Eccles et al, 1994). Family histo-
ries were verified as far as possible from medical records and death
certificates. Blood was taken from all recruits who consented to
molecular analysis for breast cancer predisposition genes.
Group 2
Group 2 consisted of45 women ascertained in the same clinics as
for group 1, but where the criterion for selection was the presence
of bilateral breast cancer diagnosed after 39 years of age. Patients
were ascertained and pedigrees were documented as for group 1
and blood was taken from those consenting to molecular genetic
analysis.
Group 3
Group 3 consisted of 30 women presenting to a genetics clinic
with a strong family history of breast or ovarian cancer or both.
The criteria for inclusion for mutation analysis were the avail-
ability of a suitable DNA sample from an affected relative and an
a priori chance that the family history was due to a dominant
predisposition gene of greater than 75%. For a family history of
breast cancer, at least two breast cancer cases diagnosed at an
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Table 1 Protein truncating mutations detected in groups 1-3
Selection Number of BRCA1 Per cent with
criteria casesa mutations detectable
analysed detected mutations
Group 1 (all cases < 40 years) 155 10 6.5
Group2 45 0 -
Group 3 30 8 26.7
Group 1
No FH 86 1 1.2
Strong FHb 40 9 22.5
All bilateral cases groups 1 and 2 61 3 4.9
All cases with strong FHb 83 17 20.5
aCase, breast cancer. bStrong FH,
group 3.
a family history meeting criteria for
average age of 40 years or less were required for inclusion. For
breast and ovarian cancer, at least one breast cancer under 45 and
one ovarian cancer under 60 were required.
Mutation analysis by heteroduplex (HD)/single-strand
conformational polymorphism (SSCP) analysis
Coding exons of BRCA1 were amplified from genomic DNA
using the primers described by Miki et al (1994). For exon 11, 18
overlapping pairs ofprimers were used as described by Gayther et
al (1995). Polymerase chain reactions (PCRs) were performed in
10-gl volumes with the inclusion of 1 ,uCi of [x-32P]dCTP.
Samples were denatured by addition of an equal volume of 95%
formamide, heated at 80°C for 5 min then electrophoresed through
a 20 cm x 45 cm x 0.4 mm non-denaturing 0.6 x MDE matrix.
Gels were run at 200-300 V overnight then dried and exposed to
X-ray film for 2-24 h. Samples with aberrant bands were
sequenced by first purifying the PCR product using the Wizard
PCR prep system (Promega) and sequencing using the Thermo
Sequenase cycle sequencing kit (Amersham).
RESULTS
A total of 18 probands from all three groups had mutations
detected in the BRCA1 gene, all of which were protein truncating.
The location of these mutations, the ratio of breast to ovarian
cancer for each family and the group from which samples were
drawn are indicated in Figure 1. There was in addition a missense
mutation (2640 C > T), elsewhere described as a low penetrance
mutation (Barker et al, 1996). This missense alteration occurred in
a family with two cases of breast cancer age 39 and 50 years at
onset with an elderly intervening female relative.
The proportion of probands with detectable mutations varied
according to selection criteria as expected and are summarized in
Table 1.
Group 1
A total of 10/155 (6.5%) had detectable mutations. In total, 86
patients in group 1 were isolated cases of breast cancer in whom
1/86 (1.2%) had a mutation - in fact this patient's paternal grand-
mother died in her 60s ofan intra-abdominal malignancy and there
were no other close female relatives on that side of the family.
Sixty-nine patients had at least one other relative with breast or
ovarian cancer and 40 patients had a strong history, which would
have qualified them for entry under the group 3 criteria. In this
subselection 9/40 (22.5%) had a mutation.
Group 2
None of this group of patients had detectable BRCAI mutations.
Twenty had a family history of at least one other relative with
cancer (breast or ovarian). Fourteen probands in this group had at
least one other relative with breast cancer and in one family ovarian
cancer. Including the 16 bilateral cases diagnosed under 40 years of
age from group 1, 3/61 probands (4.9%) had detectable mutations.
Group 3
In total, 8/30 (26.7%) of this group had detectable mutations. A
total of 16/30 families had ovarian as well as breast cancer; 7 of
these 16 (43.8%) had detectable mutations, whereas only 1 of the
remaining 14 (7.1%) ofbreast cancer-only families had detectable
mutations. Selecting from groups 1, 2 and 3 those families who
would meet the criteria for group 3, we would have detected muta-
tions in 17/84 (20.5%) of cases. In our series the most effective
selection criterion for mutation detection was early onset and a
positive family history. Bilaterality was not a useful criterion over
and above early onset or strong family history.
Table 2 Laboratory costsa
Analysis strategy Costings per case Total cost per case analysed (£)
Entire gene
Reagents (50 PCR reactions) £50 per case
Staff time @ 3 h per case £30 per case 80
Sequencingb £25 per mutation 25
Limited exons
Reagents (three PCR reactions) £4 per case
Staff time @ 1.8 h per case £16 per case 20
Sequencing (staff and reagents)b £25 per mutation 25
aCosts for time and consumables vary according to the technique used. The relative cost should be much the same. These costings do not take
overheads into account, which is relevant in absolute terms of cost for a National Health Service (NHS) molecular genetics laboratory. bThis
cost is the same whatever the selection criteria as polymorphisms will occur at equal rates across groups and costs are worked out 'per
mutation detected' for Table 3.
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Table 3 Cost effectiveness of BRCA1 mutation analysis in the general population and in groups 1 and 3
Cases selected for strong
General population All cases < 40 family history
All Limited All Limited All Limited
BRCA1 mutations detected (%) 0.07 0.04 > 6.5 6.5 > 26.7 26.7
Number screened to detect 1 mutation 1428 2.500 < 15.4 15.4 < 3.7 3.7
Cost per mutation detected £114,240 £50,000 <£1144 £308 <£328 £74
Cost analysis
Table 2 illustrates the elements of the mutation analysis that were
costed. Table 3 compares the cost per mutation detected in the
general population with those selected purely on the basis of an
index case with breast cancer under 40 years and for group 3 in
which strict selection criteria were applied.
The expected detection rates for BRCA] mutations in a general
population screen have been estimated because such a population
screen has not been done; we have estimated the detection rate on
the basis of a highly penetrant breast cancer predisposition gene
with a frequency of 0.003 in the population (Claus et al, 1991;
Iselius et al, 1992) and the observation that roughly one-third of
hereditary breast cancer may be accounted for by BRCA], one-
third by BRCA2 and one-third by as yet undiscovered genes. With
a technique that is 70% sensitive we would expect to detect muta-
tions in 1/1000 x 0.07 = 0.0007.
Therefore, in order to detect one mutation we would need to test
1/0.0007 = 1428 samples. The same argument can be applied to
the selection criteria used for groups 1 and 3 and costed according
to how extensive a mutation screen is carried out.
Targeted mutation analysis
In view of our results (in keeping with many other groups)
showing that certain mutations recur in our local population, and
because we have selected not just patients with a strong family
history for analysis, we are likely to have exposed the majority of
detectable mutations in our population. Most routine techniques
for mutation screening detect only about 70-80% ofthe mutations
present. Taking the mutations we have detected and redesigning
the primer sets, for example reducing the three sets used to detect
the mutations at the 3' end ofexon 11 to a single set, we can detect
the ten mutations with six primer sets (indicated in Figure 1 as
'regional primer set'), each giving different-sized products that can
be multiplexed in three reactions. The costs ofthis strategy are low
and the mutation detection rate should be close to 100% of those
mutations detected here. Families in which the history of
breast/ovarian cancer is compelling and in which no mutation is
detected with this limited analysis can then be entered into a more
extensive mutation analysis. Ifnovel mutations are detected during
this more extensive mutation search, suitable primers can be
designed and incorporated into the regional primer set.
DISCUSSION
The proportion of mutations detected in group 1 was 6.5%. This
figure is remarkably similar to the proportion of women with
breast cancer under40 years ofage estimated by genetic epidemio-
logical methods to be caused by mutations in the BRCAJ gene of
5.3% (Ford 1995) and found in practice by others (Langston et al,
1996; Struewing et al, 1996; Couch et al, 1997).
It is perhaps surprising that we have not detected mutations
in the bilateral breast cancer cases. However the average age at
* 4l58delAG
2804del M 13
1Jh23 3
3875deln4 G4 k3_ 1 3
11 37 de Gr 259 de C in 430 Grl
..._1
_ 3
5-W82 ins C
_._ .I. . _ : .I . ... _. ....._;. Ji i.
2 3 5 6 7 8 910 11 12 13 14 15 16 17 191 211 23 24
18 20 22
0
Figure 1 BRCA 1 mutations detected in Wessex families. The proportion of breast (dark) to ovarian (light) cancer cases is indicated for each family in which a
mutation was detected. The number to the right of each family represented indicates whether the family was ascertained through group 1 or group 3. *Two
individuals with breast cancer under 40 ascertained independently in group 1, but who were from the same family
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diagnosis of the first primary in this group was 53 years. Bilateral
breast cancer is always difficult to define as some cases will be due
to tumour metastasis and only when the primary tumour types
differ can one be certain of a true second primary. Selecting the 16
bilateral cases in group 1 (first primary diagnosed under 40 years)
there were three (19%) BRCA1 mutations.
Clearly, in group 3, in which selection was made on the basis of
a high a priori chance of a genetic basis to disease, we expected
(and found) a much higher incidence of mutations. Taking group
1, however, and applying the same selection criteria as to group 3
would have missed only one of the protein-truncating mutations
and one missense mutation of uncertain pathological significance
(which at present is unlikely to be used as a predictive test in clin-
ical practice) and we would have increased the proportion in
whom a mutation was detected to 22.5%. For a combined BRCAJ
and BRCA2 mutation analysis programme that prioritized samples
according to the likelihood offinding a mutation in either gene, the
additional cost of analysing both genes would be more than
compensated by the increase in mutations detected.
A common ancestor is likely to explain recurrent mutations in a
defined geographical region, although this has not yet been
confirmed with haplotype analysis for our population. This has
clearly been shown in a number of defined ethnic and geograph-
ical populations (Struewing et al, 1995; Johannsson et al, 1996;
Peelan et al, 1997; Richards et al, 1997; Thorlacius et al, 1997).
Redesigning primers for SSCP/HD analysis of the regionally
detected mutations allows a cheap initial mutation detection
strategy and is likely to be the most appropriate approach in a
regionally based diagnostic genetics laboratory. An alternative
strategy would be to use a protein truncation test for exon 11 of
BRCA], but this would increase both the expense and complexity
of the test without significantly increasing the sensitivity, and in
the context of a regional genetics laboratory would be the less
favoured approach.
Because of the nature of mutations in BRCAJ, unless a patient
comes from a specific ethnic group in whom a small number of
mutations accounts for the majority of familial disease (e.g.
Ashkenazim), exhaustive screening for mutations must necessarily
encompass the entire coding sequence. Even then causative muta-
tions will not always be identified, as most techniques in use in
routine genetic laboratories will detect only 70-80% of mutations.
Furthermore, mutations in BRCAJ and BRCA2 account for only
about three-quarters of strong family histories and much less in
less striking histories, with other genes still to be discovered
(Couch et al, 1997; Schubert et al, 1997). Thus, there is no clinical
benefit from screening for mutations in BRCAI (even if BRCA2
were also examined) ifthe outcome is negative (i.e. no mutation is
found) because the statistical chance ofa cancer on the basis ofthe
strong family history cannot be reduced significantly in most
cases. However, by first defining the mutations most frequently
seen in a population within a given geographical area, and then
analysing only for these in a defined patient set, the cost can be
kept low and the cost per mutation detected can be quantified.
More extensive and costly mutation analysis can be reserved for
families in which no mutation is detected but a genetic predisposi-
tion is certain. Newly detected mutations in exhaustively screened
families can then be included in the limited analysis. Families
in which an exhaustive search for mutations is negative may at
least in some cases be explained by mutations in other genes
and would therefore be extremely useful in further research into
such genes.
Clinical availability of mutation testing is now a reality in some
regions of the UK as part of a comprehensive genetics service
where the results are unlikely to be misinterpreted. However, if
commercially available BRCA] and BRCA2 mutation testing
becomes widely accessible, adverse outcomes for ill-prepared
patients might be predicted (Healy, 1997). At present, such testing
is unlikely to become a routinely accessed test from breast cancer
clinics and general practice, but once the benefits can be better
clarified it may be appropriate to consider more generally avail-
able testing ofselected cancer patients. There is still much to learn,
not only about clinical management but also about genotype-
phenotype correlations, the effects ofenvironmental factors and of
other genes in modifying the effects of inherited cancer predispo-
sition genes (Easton 1997; Struewing et al, 1997).
In conclusion, if mutation analysis is to become widely avail-
able we need a rational strategy with which to provide such a
service at a reasonable cost. Regional testing for common muta-
tions would provide a relatively inexpensive first line of analysis
that could be expected to detect the majority of mutations present
and could be carried out with ease in any regional genetics labora-
tory. Subsequent more detailed analysis could be restricted to
families with a very high likelihood of detecting a mutation (for
example, breast/ovarian cancer families with three or more cancers
in close relatives). Given the less than 100% detection capacity of
most starndard molecular genetic mutation screening protocols, it
seems acceptable to reduce substantially the cost of analysis for
only a small reduction in sensitivity.
ACKNOWLEDGEMENTS
The Wessex Cancer Trust (funding), Wessex Breast Surgeons
(access to clinics), Bridget Dunn for sample and pedigree collec-
tion, Paul Roderick (Institute of Public Health Medicine) for
helpful comments.
REFERENCES
Barker DF, Almeida E, Casey G, Fain PR, Liao SY, Masunaka I, Noble B, Kurosaki
T and Anton-Culver H ( 1996) BRCA1 R841W - a strong candidate for a
common mutation with moderate phenotype. Genietic Epidemiol 13: 595-604
Claus EB, Risch N and Thompson WD (1991) Genetic analysis ofbreast cancer in
the cancer and steroid hormone study. Amn JHlum Geniet 48: 232-242
Couch F, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campbeau L.
Ganguly A, Rebbeck TR and Weber BL (I1997) BRCA1 mutations in women
attending clinics that evaluate the risk of breast cancer. N E,gl J Med 336:
1409-1415
Easton D (1997) Breast cancer genes - what are the real risks? Noture Geniet 16:
210-211
Eeles R (1996) Testing for the breast-cancer predisposition gene, BRCA1 -
documenting the outcome in gene carriers is essential. Br MelJ 313: 572-573
Eccles, DM, Marlow A, Royle GT, Collins A and Morton NE (1994) Genetic
epidemiology ofearly onset breast cancer. J Med Geniet 31: 944-949
Ford D, Easton D and Peto J (1995) Estimates of the gene frequency ofBRCA1 and
its contribution to breast and ovarian cancer incidence. Amn JHuml Genzet 51:
1457-1462
Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S.
Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D,
Clayton D, Stratton MR and Ponder B (1995) Germline mutations of the
BRCAI gene in breast and ovarian cancer families provide evidence for a
genotype-phenotype correlation. Noiture Genie 11: 428-433
Healy B (1997) BRCA genes - bookmaking, fortunetelling, and medical care. Next
Enigl JMed 336: 1448-1449
Iselius L, Slack J, Littler M and Morton NE ( 1992) Transmission of breast cancer: a
controversy resolved. Cliii Geniet 41: 211-217
Johannsson 0. Ostermeyer EA, Hakansson S. Friedman LS, Johansson U, Sellberg
0. Brondum-Nielson K. Sele V. Olsson H. King M and Borg A (1996)
British Journal of Cancer (1998) 77(12), 2199-2203 C Cancer Research Campaign 1998BRCAl mutations in southern England 2203
Founding BRCA1 mutations in hereditary breast and ovarian cancer in
Southem Sweden. Am JHum Genet 58: 441-450
Langston AA, Malone KE, Thompson JD, Daling J and Ostrander EA (1996)
BRCA1 mutations in a population-based sample ofyoung women with breast
cancer. NEnglJMed334: 137-142
Miki Y, Swensen J, Shattuck-Eidens D, Futreal FA, Harshman K, Tavtigian S, Lui Q,
Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T,
McClure M, Frye C, Hattier T, Phelps R, Haugenstrano A, Katcher H, Yakumo
K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P,
Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P,
Rosteck P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S,
Cannonalbright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH (1994)
A strong candidate gene for the breast and ovarian cancer susceptibility gene
BRCA1. Science 266: 66-71
Peelan T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland
AMW, Hogervorst F, Brohet R, Ligtenberg MJL, Teugels E, Van der Luijt R,
Van der Hout AH, Gille JJP, Pals G, Dedema I, Olmer R, Van Leeuwen I,
Newman B, Plandsoen M, Van der Est M, Brink G, Hageman S, Arts PJW,
Bakker MM, Willems HW, Van der Looij E, Neyns B, Bonduelle M, Jansen R,
Obsterwijk JC, Sijmons R, Smeets HJM, Van Asperen CJ, MeijersHeijoboer H,
Kliju JCG, De Greve J, King MC, Menko FH, Brunner HG, Halley D, Van
Ommen GJB, Vasen HFA, Comelisse CJ, Vant Veer LJ, De KnijffP, Bakker E
and Deville P (1997) A high proportion ofnovel mutations in BRCA1 with
strong founder effects among Dutch and Belgian hereditary breast and ovarian
cancer families. Am J Hum Genet 60: 1041-1049
Rebbeck TR, Couch F, Kant J, Calzone K, DeShano M, Peng Y, Chen K, Garber JE
and Weber BL (1997) Genetic heterogeneity in hereditary breast cancer: role of
BRCA1 and BRCA2. Am J Hum Genet 59: 547-553
Richards CS, Ward PA, Roa BB, Friedman LS, Boyd AA, Kuenzli G, Dunn JK and
Plon SE (1997) Screening for 185delAG in the Ashkenazim. Am JHum Genet
60:1085-1098
Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL and
King M (1997) BRCA2 in American families with four or more cases ofbreast
or ovarian cancer: recurrent and novel mutations, variable expression,
penetrance, and the possibility offamilies whose cancer is not attributable to
BRCA1 or BRCA2. Am JHum Genet 60: 1031-1040
Serova 0, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar DE, Narod
SA, Lynch HT and Lenoir G (1997) Mutations in BRCAt and BRCA2 in
breast cancer families: are there more breast cancer-susceptibility genes. Am J
Hum Genet 60: 486-495
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Fourquet
A, Salmon RJ, Clough KB, Pouillart P, Institute Curie Breast Cancer Group,
Bonaiti-Pellie C and Thomas G (1997) BRCA I sequence variations in 160
individuals referred to a breast/ovarian family cancer clinic. Am JHum Genet
60:1021-1030
Struewing J, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS and Brody
LC (1995) The carrier frequency ofthe BRCA1185delAG mutation is
approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11:
198-200
Struewing J, Tarone RE, Brody L, Li FP and Boice JD (1996) BRCA1 mutations in
young women with breast cancer. Lancet 347: 1493
Struewing J, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M,
Timmerman MM, Brody L and Tucker MA (1997) The risk ofcancer
associated with specific mutations of BRCA1 and BRCA2 amongst Ashkenazi
Jews. New Engl JMed336: 1401-1408
Thorlacius S, Sigurdsson S, Bjamadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir
L, Tulinius H and Eyfjord JE (1997) Study ofa single BRCA2 mutation and
high carrier frequency in a small population. Am JHum Genet 60: 1079-1084
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory
S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P et al
(1995) Identification ofthe breast cancer susceptibility gene BRCA2. Nature
378: 789-792
© CancerResearch Campaign 1998 British Journal ofCancer (1998) 77(12), 2199-2203